Metformina + Dapagliflozina Generis

Metformin Hydrochloride and Dapagliflozin, the active ingredient in Metformina + Dapagliflozina Generis, is a biguanide and SGLT2 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients. GNH USA supplies Metformina + Dapagliflozina Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Dapagliflozina Generis is used in the management of type 2 diabetes mellitus, acting on both hepatic glucose production and renal glucose reabsorption. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (add‑on therapy): provides additional glycaemic control when metformin alone is insufficient. - Type 2 diabetes mellitus with renal impairment: offers glucose lowering with reduced risk of hypoglycaemia.

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Genital mycotic infection: increased risk of yeast infections in both sexes. - Urinary tract infection: symptoms of dysuria or increased frequency. - Mild hypoglycaemia: especially when used with insulin or sulfonylureas. - Dehydration: due to osmotic diuresis.

Serious or Rare Side Effects: - Diabetic ketoacidosis: metabolic acidosis with elevated ketones. - Lactic acidosis: rare but life‑threatening accumulation of lactate. - Severe hypoglycaemia: profound low blood glucose requiring emergency care. - Acute kidney injury: sudden decline in renal function. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Patients should be evaluated for renal and hepatic function before initiating therapy and monitored regularly. - Renal function monitoring: assess eGFR prior to start and periodically thereafter. - Hepatic impairment: avoid in severe liver disease due to lactic acidosis risk. - Risk of ketoacidosis: educate patients on signs, especially during illness or reduced food intake. - Volume depletion: advise adequate hydration, especially in hot climates. - Pregnancy and breastfeeding: use only if clearly needed after risk‑benefit assessment. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Co‑administration with certain drugs can alter efficacy or increase adverse events.

Major Interactions (Avoid): - Other SGLT2 inhibitors: additive risk of ketoacidosis. - Iodinated contrast agents in patients with renal dysfunction: may precipitate acute kidney injury. - Strong CYP3A4 inhibitors (e.g., ketoconazole) with dapagliflozin: increase exposure.

Moderate Interactions (Monitor Closely): - Cimetidine or other renal‑clearance reducing agents: may raise metformin levels. - Loop or thiazide diuretics: heightened risk of volume depletion. - NSAIDs: potential impact on renal function when combined with metformin. - Insulin or sulfonylureas: increased likelihood of hypoglycaemia.